Observation study for the application of phosphocreatine injection in patients with heart failure and sarcopenia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032916

Enrollment

Unknown

Registered

2020-05-15

Start date

2020-05-14

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Two groups:phosphocreatine versus normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients who voluntarily participate, understand and sign informed consent; 2. NYHA heart function grade II-IV in patients with heart failure diagnosis criteria: (1) Echocardiography has abnormal cardiac structure with abnormal systolic or diastolic function. LVEF does not make specific regulations; (2) Have at least one heart failure symptom and one physical sign or chest radiograph result 3. Heart failure symptoms: (1) Dyspnea occurs when breathing is difficult or slight activity occurs in a resting state; (2) Fatigue; (3) Decreased activity tolerance; 4. Signs of heart failure: (1) Moist rales appeared in lung field; (2) Peripheral edema; (3) Increase of jugular vein pressure or neck vein distention; 5. Patients with pulmonary congestion or edema indicated by chest film; 6. NT-proBNP>=1000pg/ml; 7. Patients who meet the diagnostic criteria for sarcopenia proposed by the Asian Working Group on sarcopenia in 2016.

Exclusion criteria

Exclusion criteria: 1. Patients with different intention; 2. Patients who have poor compliance or are unable to participate in the trial due to serious clinical conditions; 3. Patients with severe liver and kidney function damage; 4. Patients who had undergone major cardio cerebrovascular surgery within 3 months before randomization, or expected to undergo major cardio cerebrovascular surgery within 3 months; 5. Patients who are allergic to sodium creatine phosphate; 6. Patients with other muscle diseases or other diseases affecting physical activity.

Design outcomes

Primary

Measure	Time frame
NT-proBNP;LVEF;Muscle mass;Quantity and quantity of exosome protein;Expression of mitochondrial protein marker in exosomes;Inflammatory factor level;	—

Countries

China

Contacts

Public ContactYanqiu Xing

Qilu Hospital of Shandong University

xingyanqiu@sina.com+86 18560082269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026